AMAG Pharma (AMAG) Tops Q2 EPS by 25c
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
AMAG Pharma (NASDAQ: AMAG) reported Q2 EPS of $1.45, $0.25 better than the analyst estimate of $1.20. Revenue for the quarter came in at $127.4 million versus the consensus estimate of $128.52 million.
AMAG Pharma sees FY2016 revenue of $503-553 million, versus the consensus of $533.8 million.
For earnings history and earnings-related data on AMAG Pharma (AMAG) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Twitter (TWTR) Tops Q3 EPS by 4c; Announces Restructuring, Workforce Reduction
- Celgene (CELG) Tops Q3 EPS by 10c; Boosts FY16 EPS Outlook
- Intelsat S. A. (I) Tops Q3 EPS by 6c; Reaffirms
Create E-mail Alert Related CategoriesEarnings, Guidance
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!